ASH1L and breast cancer: We found that, similar to primary breast cancer samples, 16 of 17 lines showed gain or amplification in at least one locus of SETDB1, ASH1L, SMYD2, and SMYD3. Six lines (Colo824, HCC70, HCC1187, MDB-MA-468, HCC1954, and ZR-75-1) showed low-level gain across most of chromosome 1q, whereas Colo824 and HCC1187 showed high-level amplification at the SETDB1 locus (Figure 4B and Supplementary Table S4).